TY - JOUR A1 - Jessberger, Steffen A1 - Högger, Petra A1 - Genest, Franca A1 - Salter, Donald M. A1 - Seefried, Lothar T1 - Cellular pharmacodynamic effects of Pycnogenol\(^{®}\) in patients with severe osteoarthritis: a randomized controlled pilot study JF - BMC Complementary and Alternative Medicine N2 - Background: The standardized maritime pine bark extract (Pycnogenol\(^{®}\)) has previously shown symptom alleviating effects in patients suffering from moderate forms of knee osteoarthritis (OA). The cellular mechanisms for this positive impact are so far unknown. The purpose of the present randomized pilot controlled study was to span the knowledge gap between the reported clinical effects of Pycnogenol\(^{®}\) and its in vivo mechanism of action in OA patients. Methods: Thirty three patients with severe OA scheduled for a knee arthroplasty either received 100 mg of Pycnogenol\(^{®}\) twice daily or no treatment (control group) three weeks before surgery. Cartilage, synovial fluid and serum samples were collected during surgical intervention. Relative gene expression of cartilage homeostasis markers were analyzed in the patients' chondrocytes. Inflammatory and cartilage metabolism mediators were investigated in serum and synovial fluid samples. Results: The oral intake of Pycnogenol\(^{®}\) downregulated the gene expression of various cartilage degradation markers in the patients' chondrocytes, the decrease of MMP3, MMP13 and the pro-inflammatory cytokine IL1B were statistically significant (p ≤ 0.05). Additionally, protein concentrations of ADAMTS-5 in serum were reduced significantly (p ≤ 0.05) after three weeks intake of the pine bark extract. Conclusions: This is the first report about positive cellular effects of a dietary supplement on key catabolic and inflammatory markers in patients with severe OA. The results provide a rational basis for understanding previously reported clinical effects of Pycnogenol\(^{®}\) on symptom scores of patients suffering from OA. KW - maritime pine bark extract KW - qPCR KW - ADAMTS KW - cartilage KW - clinical study KW - osteoarthritis KW - Pycnogenol KW - serum KW - synovial fluid Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-159532 VL - 17 IS - 537 ER - TY - JOUR A1 - Sattler, Janko A1 - Noster, Janina A1 - Brunke, Anne A1 - Plum, Georg A1 - Wiegel, Pia A1 - Kurzai, Oliver A1 - Meis, Jacques F. A1 - Hamprecht, Axel T1 - Comparison of two commercially available qPCR kits for the detection of Candida auris JF - Journal of Fungi N2 - Candida auris is an emerging pathogen with resistance to many commonly used antifungal agents. Infections with C. auris require rapid and reliable detection methods to initiate successful medical treatment and contain hospital outbreaks. Conventional identification methods are prone to errors and can lead to misidentifications. PCR-based assays, in turn, can provide reliable results with low turnaround times. However, only limited data are available on the performance of commercially available assays for C. auris detection. In the present study, the two commercially available PCR assays AurisID (OLM, Newcastle Upon Tyne, UK) and Fungiplex Candida Auris RUO Real-Time PCR (Bruker, Bremen, Germany) were challenged with 29 C. auris isolates from all five clades and eight other Candida species as controls. AurisID reliably detected C. auris with a limit of detection (LoD) of 1 genome copies/reaction. However, false positive results were obtained with high DNA amounts of the closely related species C. haemulonii, C. duobushaemulonii and C. pseudohaemulonii. The Fungiplex Candida Auris RUO Real-Time PCR kit detected C. auris with an LoD of 9 copies/reaction. No false positive results were obtained with this assay. In addition, C. auris could also be detected in human blood samples spiked with pure fungal cultures by both kits. In summary, both kits could detect C. auris-DNA at low DNA concentrations but differed slightly in their limits of detection and specificity. KW - qPCR KW - detection limits KW - sensitivity KW - strain specificity KW - commercial kits KW - Candida auris KW - Fungiplex Candida Auris KW - AurisID Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-228879 SN - 2309-608X VL - 7 IS - 2 ER - TY - THES A1 - Patzina, Tobias T1 - Genetische Veränderungen am SOX9 Lokus bei Pierre-Robin-Sequenz T1 - Genetic variations at the SOX9 lokus in patients with Pierre-Robin-Sequence N2 - Die Pierre-Robin-Sequenz ist eine angeborene kraniofaziale Fehlbildung, bei der häufig eine Triade von Symptomen, bestehend aus mandibulärer Mikrognathie/Retrognathie, Glossoptose und einer Gaumenspalte, beobachtet werden kann. Aufgrund der Heterogenität der PRS und der häufigen Vergesellschaftung mit Syndromen, konnten Ätiologie und Pathogenese der PRS bisher nur unzureichend geklärt werden. Für einen Teil der Patienten mit isolierter PRS konnte eine familiäre Häufung von PRS-Fällen nachgewiesen werden, was auf eine erbliche Komponente als krankheitsauslösenden Faktor hinweist. In diesem Zusammenhang konnten bei Patienten mit isolierter PRS gehäuft genetische Veränderungen mit einer Entfernung von über 1Mb zentromerisch (5´) von SOX9 auf dem Chromosom 17 detektiert werden. Es wird vermutet, dass diese genetischen Aberrationen am SOX9 Lokus eine gewebsspezifische Fehlregulation von SOX9 während der Embryonalentwicklung auslösen und somit ursächlich für die Entstehung von PRS sein können. Das Ziel dieser Arbeit war es, eine Würzburger Patientenkohorte mit isolierter PRS zu gewinnen und Informationen über die phänotypischen Merkmale der Studienteilnehmer auszuwerten. Im Anschluss sollte die Patienten-DNS mittels molekulargenetischen Analysemethoden auf potenziell krankheitsauslösende genetische Aberrationen am SOX9 Lokus untersucht werden. Zunächst konnte eine Kohorte mit sieben PRS-Patienten erstellt und Informationen über die phänotypischen Krankheitsmerkmale erfasst und ausgewertet werden. Anschließend wurden bei den Studienteilnehmern eine Array-CGH, eine quantitative Echtzeit-Polymerase-Kettenreaktion und im Bereich von drei konservierten, potenziell regulatorischen Elementen des SOX9 Lokus eine Sanger Sequenzierung durchgeführt. Die Array-CGH ergab zunächst bei einem Patienten zwei große Deletionen im regulativen Umfeld des SOX9 Lokus, welche im Weiteren nicht durch qPCR bestätigt werden konnten. Letztendlich konnten durch die Sanger Sequenzierung 22 Varianten detektiert werden, wovon für drei Einzelnukleotid-Polymorphismen eine prädisponierende Wirkung diskutierbar und für zwei Einzelnukleotid-Varianten eine ursächlich pathogene Wirkung nicht auszuschließen ist. N2 - The Pierre-Robin-Sequence is a congenital craniofacial disorder mostly described as a triade of symptoms, consisting of mandibular micrognathia, glossoptosis and cleft palate. Due to its heterogenity, the aetiology and pathogenesis of PRS is not recognized in every case of the disease. Nevertheless familial accumulation in isolated PRS cases pointed to a possible genetic source of pathology. In this context, genetic analysis in patients with isolated PRS pointed to genetic variations far upstream (more than 1Mb) of the SOX9 gene on chromosome 17 as possibly disease-inducing. These genetic variations at the SOX9 lokus are supected to cause tissue specific misregulation of SOX9 during embryogenesis and thus can be seen as causal for the development of isolated PRS. The objective of this study was to form a group of patients with isolated PRS and to gain information about their phenotype. Subsequently, genetic analysis should be used to find potentially disease inducing genetic variations at the SOX9 lokus. A cohort of 7 patients with isolated PRS was formed and the phenotypes of these patients were registered and evaluated. In addition, array-CGH, real-time quantitative polymerase chain reaction and sanger sequencing was performed for all the participants of this study. Array-CGH resulted in two big deletions within the regulary domain of the SOX9 lokus, which could not be confirmed with qPCR. Eventually, sanger sequencing of three conserved, non coding elements at the SOX9 lokus showed 22 variants, of which three single-nucleotid polymorphisms could potentially prove to have a predisposing effect and two singlenucleotid-variants, for which a pathogenic effect cannot be ruled out. KW - Robin-Syndrom KW - Mikroarray KW - CNV KW - Sanger Sequenzierung KW - Sanger sequencing KW - quantitative Polymerasekettenreaktion KW - qPCR KW - Mikroarray KW - SOX9 Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-186893 ER -